| UNITED STATES | |
| SECURITIES AND EXCHANGE COMMISSION | |
| Washington, D.C. 20549 | |
| Notice of Effectiveness | |
| Effectiveness Date: | December 18, 2024 4:30 P.M. |
| Form: | S-3 | ||||||
| |||||||
| UNITED STATES | |
| SECURITIES AND EXCHANGE COMMISSION | |
| Washington, D.C. 20549 | |
| Notice of Effectiveness | |
| Effectiveness Date: | December 18, 2024 4:30 P.M. |
| Form: | S-3 | ||||||
| |||||||
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
HORSHAM, Pa., Dec. 09, 2025 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. (NASDAQ:SSKN), a global leader in in-office dermatologic technologies, announces its participation in the 2025 Ibero-Latin American Congress of Dermatology (TeraCILAD) November 19-22, 2025, where it presented its XTRAC® excimer laser and TheraclearX® acne therapy system. STRATA also reported that, by the end of 2025, there will be over 12 new recurring TheraclearX® accounts in Mexico, reflecting growing adoption of this innovative acne treatment modality by dermatologists in the region. Key Highlights STRATA showcased XTRAC®, the leading targeted UVB excimer laser for psoriasis, vitiligo, and other skin conditions
HORSHAM, Penn., Nov. 13, 2025 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. ("STRATA" or the "Company") (NASDAQ:SSKN), a medical technology company dedicated to developing, commercializing, and marketing innovative products for the treatment of dermatologic conditions, announces its financial results for the quarter ended September 30, 2025, and provides a corporate update. Third Quarter Highlights Continued progress toward historic expansion of CPT codes for reimbursement for inflammatory and auto-immune skin diseases, effectively tripling the covered patient population in the US, including recent recognition of expanded CPT codes by the Center for Medicare and Medicaid Services (CMS)
HORSHAM, Pa., Nov. 06, 2025 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. (NASDAQ:SSKN), a global leader in excimer laser therapy for inflammatory and autoimmune dermatologic diseases, today announced that the Centers for Medicare & Medicaid Services (CMS) has issued its CY 2026 Medicare Physician Fee Schedule Final Rule confirming continued reimbursement for excimer laser treatments under CPT® codes 96920, 96921, and 96922, while recognizing the upcoming expansion of CPT code descriptors to include inflammatory and autoimmune skin conditions beyond psoriasis—effective January 1, 2027. In the Final Rule, CMS recognized the excimer laser as a well-established treatment modality, affirmed
4 - STRATA Skin Sciences, Inc. (0001051514) (Issuer)
4 - STRATA Skin Sciences, Inc. (0001051514) (Issuer)
4 - STRATA Skin Sciences, Inc. (0001051514) (Issuer)
4 - STRATA Skin Sciences, Inc. (0001051514) (Issuer)
4 - STRATA Skin Sciences, Inc. (0001051514) (Issuer)
4 - STRATA Skin Sciences, Inc. (0001051514) (Issuer)
8-K - STRATA Skin Sciences, Inc. (0001051514) (Filer)
8-K - STRATA Skin Sciences, Inc. (0001051514) (Filer)
10-Q - STRATA Skin Sciences, Inc. (0001051514) (Filer)
Apyx Medical Corporation (NASDAQ:APYX) ("Apyx Medical;" the "Company"), the manufacturer of a proprietary helium plasma and radiofrequency technology marketed and sold as Renuvion®, today announced the appointment of Matthew Hill to the position of Chief Financial Officer, effective December 4, 2023. Mr. Hill succeeds Tara Semb, whose departure was announced by the Company on November 9, 2023. "Matt joins our executive leadership team with over 30 years of financial and operational experience, more than 20 years of which has been in the healthcare industry, where he has served as the Chief Financial Officer of four publicly-traded healthcare companies," said Charlie Goodwin, President and
HORSHAM, Pa., June 30, 2023 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. (NASDAQ:SSKN), a medical technology company dedicated to developing, commercializing and marketing innovative products for the treatment of dermatologic conditions, today announced the appointment of Dr. Uri Geiger as the Chairman of the Board of Directors. William Humphries will step down as Chairman and continue to serve on the Board, effective July 3, 2023, as he transitions into his role as Chief Executive Officer of Alcami Corporation. "I'm honored to assume the role of Chairman at this pivotal moment in STRATA's growth," said Dr. Uri Geiger, Chairman of STRATA's Board of Directors. "I look forward to levera
HORSHAM, Pa., Feb. 14, 2022 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. (NASDAQ:SSKN), a medical technology company dedicated to developing, commercializing and marketing innovative products for the treatment of dermatologic conditions, announced that effective today, Patricia S. Walker M.D., PhD. has been appointed to its Board of Directors. Dr. Walker's vast experience includes more than 35 years as a practicing dermatologist and as a corporate leader in the medical dermatology, medical aesthetics and pharmaceutical industries, executing clinical research and strategic initiatives for a wide range of companies and educational institutions. "We are delighted to welcome Patty to STRAT
SC 13G/A - STRATA Skin Sciences, Inc. (0001051514) (Subject)
SC 13D/A - STRATA Skin Sciences, Inc. (0001051514) (Subject)
SC 13G/A - STRATA Skin Sciences, Inc. (0001051514) (Subject)
HORSHAM, Penn., Nov. 05, 2025 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. ("STRATA" or the "Company") (NASDAQ:SSKN), a medical technology company dedicated to developing, commercializing, and marketing innovative products for the treatment of dermatologic conditions, announces that it will report third quarter 2025 financial results on Thursday, November 13, 2025 after the market close. STRATA management will subsequently host a conference call at 4:30 p.m. ET on Thursday, November 13, 2025 to review financial results and provide an update on corporate developments. Following management's formal remarks, there will be a question-and-answer session. To listen to the conference call, in
HORSHAM, Penn., Aug. 13, 2025 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. ("STRATA" or the "Company") (NASDAQ:SSKN), a medical technology company dedicated to developing, commercializing, and marketing innovative products for the treatment of dermatologic conditions, announces its financial results for the quarter ended June 30, 2025, and provides a corporate update. Second Quarter Highlights Historic expansion of CPT codes for reimbursement for inflammatory and auto-immune skin diseases, effectively tripling the covered patient population in the USPotential acceleration of expanded reimbursement coverage through application for G-codes to gain access by 2026 cycleSubmission of econom
HORSHAM, Pa., July 31, 2025 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. ("STRATA" or the "Company") (NASDAQ:SSKN), a medical technology company dedicated to developing, commercializing, and marketing innovative products for the treatment of dermatologic conditions, announces that it will report second quarter 2025 financial results on Wednesday, August 13, 2025 after the market close. STRATA management will subsequently host a conference call at 4:30 p.m. ET on Wednesday, August 13, 2025 to review financial results and provide an update on corporate developments. Following management's formal remarks, there will be a question-and-answer session. To listen to the conference call, i